



UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
097600,991	09/15/00	MEDICO	E 471-162F

002292

HM11/1004

BIRCH STEWART KOLASCH & BIRCH

PO BOX 747

FALLS CHURCH VA 22040-0747

EXAMINER

WEGERT, S

ART UNIT

1647

PAPER NUMBER

DATE MAILED: 10/04/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office of the

The Secretary of the

The Chief of the

Applicant may not be aware of the

The proposed drawing is intended to

If approved, copies of the drawing will be

The path of the drawing is provided by the

under 35 U.S.C. §§ 113 and 116

Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a) or (b)

All of Some of None of

Certified copies of the priority documents have been received

Certified copies of the priority documents have been received in Application No.

Copies of the certified copies of the priority documents have been received in the National Stage application from the International Bureau (PCT Rule 17.2(a)).

See the attached detailed Office action for a list of the certified copies not received.

Applicant is hereby notified of a claim for foreign priority under 35 U.S.C. § 119(e) for a foreign priority claim.

The translation of the foreign language provisional application has been received.

Applicant is hereby notified of a claim for foreign priority under 35 U.S.C. §§ 119 and 120.

Office Action Summary

Application No.

09/600,991

Applicant(s)

MEDICO ET AL.

Examiner

Sandra Wegert

Art Unit

1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 20 August 2001.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-13 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-13 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

- I. Claims 1, 2, 3, 10 and 13, drawn to polypeptides of the formula: $LS_{MSP}-HL_{MSP}-K1_{MSP}-K2_{MSP}-L-HL_{HGF}-K1_{HGF}-K2_{HGF}-D$.
- II. Claims 1, 2, 4, 10 and 13, drawn to polypeptides of the formula: $LS_{HGF}-HL_{HGF}-K1_{HGF}-K2_{HGF}-L-HL_{HGF}-K1_{HGF}-K2_{HGF}-D$.
- III. Claims 5-9, drawn to polynucleotides encoding peptides of the formula: $LS_{MSP}-HL_{MSP}-K1_{MSP}-K2_{MSP}-L-HL_{HGF}-K1_{HGF}-K2_{HGF}-D$.
- IV. Claims 5-9, drawn to polynucleotides encoding peptides of the formula: $LS_{HGF}-HL_{HGF}-K1_{HGF}-K2_{HGF}-L-HL_{HGF}-K1_{HGF}-K2_{HGF}-D$.
- V. Claims 11 and 12, drawn to the methods of manufacturing a medicament.

The inventions are distinct, each from the other because of the following reasons:

The first claimed invention lacks a special technical feature because it fails to distinguish the claimed invention from the prior art (e.g., Trusolino, et al, FASEB J., 1998). The prior art discloses use of *scatter* factors, for therapeutic applications, that meet the limitations of "equivalent" polypeptides

Art Unit: 1647

recited in the first claimed invention. Therefore, none of the other claimed inventions can share a special technical feature with the first claimed invention. Furthermore, Inventions I-IV are independent and distinct, each from each other, because they are products which possess characteristic differences in structure and function and each has an independent utility that is distinct for each invention which cannot be exchanged. Each protein of Inventions I and II can be made by another and materially different process such as by synthetic peptide synthesis. The polynucleotides of Inventions III and IV can be used to make a hybridization probe, or can be used in gene therapy as well as to produce the proteins of Groups I and II. Furthermore, the peptides of Inventions I and II are related to inventions III and IV as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (M.P.E.P. § 806.05 (f)). In the instant case, the peptide may be made by chemical synthesis.

Inventions I and II are related to Invention V as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process (M.P.E.P. § 806.05 (h)). In the instant case the peptides of Invention I and II can be used for the production of antibodies.

The proteins of Invention I and the antibody of Invention IV are distinct inventions because they are products which possess characteristic differences in structure and function and each has an independent utility that is distinct for each invention which cannot be exchanged. The peptide of Invention I can be used for purposes other than to make an antibody of Group IV, such as a probe, or used therapeutically or diagnostically (e.g. in screening).

The products and methods of Inventions III and IV are distinct from the methods of Invention V because the DNA of Inventions III and IV can be neither made by nor used in the methods of Invention

Art Unit: 1647

V, and because the methods require different process steps, reagents, and parameters as well as produce different products.

In order to be fully responsive, Applicant must pick one from Inventions I-V.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, separate search requirements, and different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 C.F.R. 1.143)

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 C.F.R. 1.48(b) and by the fee required under 37 C.F.R. 1.17(i).

Advisory information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sandra Wegert whose telephone number is (703) 308-9346. The examiner can normally be reached Monday - Friday from 9:00 AM to 5:00 PM (Eastern Time). If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Gary Kunz, can be reached at (703) 308-4623.

Application/Control Number: 09/600,991

Page 5

Art Unit: 1647

Official papers filed by fax should be directed to (703) 308-4242. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

SLW

September 28, 2001.

Gary L. Kunz
GARY L. KUNZ
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600